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Background: Left ventricular (LV) abnormalities have been reported in cystic ﬁbrosis (CF); however, it remains unclear if loss of cystic ﬁbrosis
transmembrane conductance regulator (CFTR) function causes heart defects independent of lung disease.
Methods: Using gut-corrected F508del CFTR mutant mice (ΔF508), which do not develop human lung disease, we examined in vivo heart and
aortic function via 2D transthoracic echocardiography and LV catheterization.
Results: ΔF508 mouse hearts showed LV concentric remodeling along with enhanced inotropy (increased +dP/dt, fractional shortening, decreased
isovolumetric contraction time) and greater lusitropy (−dP/dt, Tau). Aortas displayed increased stiffness and altered diastolic ﬂow. β-adrenergic
stimulation revealed diminished cardiac reserve (attenuated +dP/dt,−dP/dt, LV pressure).
Conclusions: In a mouse model of CF, CFTR mutation leads to LV remodeling with alteration of cardiac and aortic functions in the absence of lung
disease. As CF patients live longer, more active lives, their risk for cardiovascular disease should be considered.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: CFTR; Cystic ﬁbrosis; Left ventricular function; Aorta1. Introduction
Cystic fibrosis (CF) has long been characterized by its effect
on epithelial tissues, however, since the discovery of the cystic
fibrosis transmembrane conductance regulator (CFTR) gene,
extensive research efforts have sought to characterize the effect
of CFTR loss on various tissues throughout the body. CFTR
expression and Cl− currents were identified in cardiac myocytes
20 years ago [1]. Despite these early findings, a defined
physiologic role for CFTR in the heart has remained largely
elusive. With its Cl− conductive properties, it has been proposed
that CFTR contributes to the maintenance of resting membrane☆ Data were presented in part at the North American Cystic Fibrosis Conference
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http://dx.doi.org/10.1016/j.jcf.2012.11.012potential and minimization of action potential prolongation
associated with stimulation of inward Ca2+ current [2,3].
Additionally, simulation studies by Kuzumoto et al. predicted
that increases or decreases in CFTR channel density would
positively or negatively alter action potential duration, respectively,
due to β-adrenergic stimulation [4]. Our prior studies examining
the effects of increasing or decreasing CFTR activity on isolated
cardiomyocyte contraction support these predictions [5,6]. Beyond
maintaining normal physiologic function, CFTR is up-regulated
during ischemia [7], involved in the protection of ischemic pre- and
post-conditioning [8,9], and down-regulated in patients with heart
failure [10].
Numerous investigators have examined heart function in CF
patients, however, with the prominent pulmonary disturbances
in CF patients, the majority of these studies have focused on the
right ventricle. Increased pulmonary pressures in individuals with
lung disease can cause cor pulmonale and right ventricular
overload [11]. In contrast, evidence for the primary left ventricular
dysfunction in CF has been scarce. Recent evidence for increased
aortic stiffness in CF children [12] and adults [13–15] has addedby Elsevier B.V. All rights reserved.
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CF. These studies, coupled with our prior experiments showing
CFTR involvement inmurine cardiomyocyte contraction [5,6] led
us to hypothesize that loss of CFTR function would lead to
primary cardiovascular disturbances independent of lung disease.
To bypass the effects of lung disease, we utilized ΔF508 CFTR
mutant mice, which do not display the lung pathology found in
CF patients [16,17]. Through the left ventricular catheterization
and 2D echocardiography, we examined cardiac and vascular
function in vivo. We found that loss of CFTR function leads to a
left ventricular remodeling, increased inotropy and lusitropy, and
diminished responsiveness to β-adrenergic stimulation, coupled
with changes in aortic stiffness and flow.
2. Methods
2.1. Animals
Gut-corrected ΔF508 CFTR mutant mice (strain C57/BL6-
Cftrtm1Kth-TgN(FABPCFTR)#Jaw/Cwr), hereto referred to as
“ΔF508”, originated from Case Western Reserve University
(Cleveland, OH), but were obtained from Dr. Deborah Nelson at
the University of Chicago (Chicago, IL) and bred in-house. These
mice are homozygous for the F508 deletion in the endogenous
mouse CFTR gene [16], but express human CFTR from the
rat fatty acid binding protein 1 promoter to prevent intestinal
obstruction. These mice were developed in a similar manner as the
gut-corrected CFTR null mouse by Zhou et al. [17]. To date there
have been no phenotypical differences between gut-corrected
CFTR null and gut-corrected ΔF508 mice (communication with
Dr. Craig Hodges, Case Western Reserve University). In the gut-
corrected null mouse, human CFTRmRNAwas detected through-
out the intestinal tract, pancreas, kidney, and brain, but not in the
heart [17]. In our prior experiments with gut-corrected ΔF508
mice, we did not observe any CFTR activity in isolated cardiac
myocytes, as evidenced by the inability of CFTRinh-172 to affect
contraction or Ca2+ signaling [5].
ΔF508 CFTR breeders were used to generate progeny for
experiments, while strain-matched controls (WT), C57/BL6
mice, were obtained from Jackson Laboratory (Bar Harbor, ME).
Adult mice (16–20 weeks) were used. There was no difference
(PN0.05) between the ages, bodyweight, or numbers of males vs.
female mice in each group of animals. In all sets of experiment,
equal numbers of each sex were used. Use of animals and
protocols was approved by University of Illinois at Urbana-
Champaign and Washington University, St Louis IACUCs.
2.2. Left ventricular catheterization
The protocol for in vivo hemodynamic studies was derived
from that of Rockman et al. [18] and carried out by the Mouse
Cardiovascular Phenotyping Core Facility at Washington
University, St. Louis. Mice were anesthetized with thiopental
sodium (60 mg/kg, intraperitoneally). This anesthesia produces a
normal heart rate of 500 beats/min while still providing a surgical
plane of anesthesia. There were no appreciable differences in
the amount of anesthesia required for WT vs. ΔF508 mice.Hemodynamic measurements were recorded at baseline and 60 s
after a constant infusion of dobutamine (Barnes-Jewish Hospital
Clinical Pharmacy, St. Louis, MO). Continuous left ventricular
(LV) systolic and diastolic pressures and their derivatives (dP/dt)
were recorded with Millar analysis software.
2.3. Echocardiography
Non-invasive ultrasound examination of the heart and aorta of
anesthetized mice was performed using a Vevo 770 Ultrasound
System. Complete 2-D,M-mode, and Doppler ultrasound utilized
short- and long-axis views. The Tei index was calculated by
the time from mitral closing to the onset of mitral opening
(isovolumetric contraction time (IVCT)+isovolumetric relaxa-
tion time (IVRT)+ejection time (ET)), divided by the time from
onset to the end of the left ventricular outflow (ET). For pulse
wave velocity measurements, the ascending aorta, aortic arch, and
proximal portion of the descending aorta were imaged in one 2-D
imaging plane. Following euthanization, hearts were removed
and weighed for comparison to body weight.
2.4. Statistics
All data are expressed as means±SEM. Unpaired Student's
t-test and one-way ANOVA with repeated measures and
Bonferonni post-test were performed by GraphPad Prism
(La Jolla, CA). Significant values are represented as *, Pb0.05;
**, Pb0.01; and ***, Pb0.001.
3. Results
3.1. CFTRmutation causes left ventricular concentric remodeling
To determine ifΔF508 CFTR mutation causes morphological
changes, we performed echocardiography of the left ventricle. In
diastole, the left ventricular posterior wall (LVPW) and inter-
ventricular septum (IVS) were significantly thickened in ΔF508
mice, with a concomitant decrease in the left ventricular internal
diameter (LVID) (Table 1). As a consequence, the LV relative
wall thickness ((LVPWd+IVSd) /LVIDd) was significantly
larger in comparison to WT mice (ΔF508: 0.54±0.02 vs. WT:
0.42±0.02, n=10, Pb0.001). Gross examination of hearts
following experiments revealed no difference in the heart:body
weight ratio of ΔF508 hearts. Despite no global enlargement of
the heart, ΔF508 mouse hearts undergo specific concentric
remodeling of the left ventricle.
3.2. Characterization of ΔF508 hearts at rest
Subsequently, we examined if ΔF508 mice exhibit altered
in vivo heart function at rest. Echocardiography showed a
significant increase in the contraction of ΔF508 hearts, as
indicated by increased fractional shortening (FS) and decreased
isovolumetric contraction time (IVCT) (Table 2). The Tei index,
an inverse measurement of overall heart performance (RV and
LV), was significantly decreased in ΔF508 mice, indicating
greater performance of ΔF508 hearts. These findings were
Table 1
Echocardiographic characterization of the left ventricular structure. The left ventricles of WT and ΔF508 mice (n=10) were examined using M-mode
echocardiography. LVPWd, LVPWs: left ventricular posterior wall during diastole or systole, respectively; IVSd, IVSs: interventricular septum during diastole or
systole, respectively; LVIDd, LVIDs: left ventricular internal diameter during diastole or systole, respectively. Values are expressed as means±SEM. *, Pb0.05;
**, Pb0.01 vs. WT by Student's t-test.
Strain Body weight
(g)
Heart:Body
(mg/g)
LVPWd
(mm)
IVSd
(mm)
LVIDd
(mm)
LVPWs
(mm)
IVSs
(mm)
LVIDs
(mm)
WT 24.61±1.35 4.57±0.10 0.73±0.03 0.73±0.02 3.46±0.09 1.17±0.04 1.22±0.05 2.04±0.07
ΔF508 23.28±0.80 4.72±0.07 0.82±0.02* 0.86±0.03** 3.11±0.05** 1.21±0.03 1.25±0.04 1.66±0.07**
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which showed increases in indices of contraction (+dP/dt) and
relaxation (−dP/dt, Tau) (Fig. 1). Additionally, ΔF508 hearts
had elevated systolic pressures, but no change in end-diastolic
pressure or heart rate.
Trans-mitral velocities and tissue Doppler (TDI) data are
presented in Table 2. These studies revealed an 8% decrease in
early filling peak velocity (E) together with a 9% increase in
late filling or atrial peak velocity (A), resulting in a significantly
decreased E/A ratio, but no change in deceleration time (DT).
TDI indicated no change in early diastole (E′), but did reveal an
increase in late diastole (A′). As a result, the E′/A′ of ΔF508
hearts was significantly decreased from their WT counterparts;
however, no change in E/E′ was observed.3.3. Altered aortic compliance and increased afterload in ΔF508
mice
Based on our findings of the left ventricular concentric
hypertrophy, increased contraction, and increased LV systolic
pressures in ΔF508 mice, we examined the aortic function of
ΔF508 mice. ΔF508 mice aortas had significantly decreased
internal diameters during both systole and diastole compared to
WT mice (Fig. 2A), and were significantly less distensible than
WT aortas (Fig. 2B). Furthermore, pulse wave velocity measure-
ments showed that ΔF508 mice had a significant increase in
velocities compared to WT mice, indicating an increase in aortic
stiffness (Fig. 2C). In ΔF508 mice, examination of the flow
pattern within the aorta showed decreased diastolic forward
velocity and increased diastolic retrograde velocity (Fig. 2D).
There were no differences in aortic valve function between either
groups of animals (data not shown). Thus, in vivo, ΔF508 aortas
are stiffer and less distensible, leading to alterations in aortic blood
flow.Table 2
Echocardiographic measurement of resting left ventricular function. Echocardiograph
shortening. E: early filling peak velocity; A: late filling or atrial peak velocity; DT:
velocity; IVCT, IVRT: isovolumetric contraction or relaxation time, respectively. Va
t-test.
Strain FS
(%)
E
(cm/s)
A
(cm/s)
E/A DT
(ms)
S′
(cm/s)
E′
(cm/s)
WT 41.0±1.2 777±28 591±30 1.33±0.07 16.6±1.0 22.7±0.8 25.6±1
ΔF508 46.9±1.4* 715±17 645±17 1.12±0.04* 16.2±0.7 21.0±0.7 26.3±13.4. β-adrenergic stimulation reveals altered cardiac reserve
We further explored the functional characteristics of ΔF508
hearts via catheterization studies; wherein WT and ΔF508
mouse hearts were stimulated with incremental increases of the
β-adrenergic agonist dobutamine. In both WT and ΔF508 mice,
dobutamine caused significant changes in all measurements
(Pb0.05). However, while ΔF508 mice retained the ability to
respond to dobutamine with increased contraction and relaxation,
compared toWTmice, they had significantly diminished changes
from baseline with a 49% reduction in +dP/dt, 51% decrease in
−dP/dt, and 80% relative decrease in the left ventricular systolic
pressure (Fig. 3). Additionally, while similar at lower concentra-
tions, at maximal stimulation, ΔF508 mice had a significantly
larger decrease in LVEDP than WT mice. There were no
differences in HR or Tau between WT and ΔF508 mice at any
dobutamine dose. Thus, in addition to changes at rest, ΔF508
mice display altered responses when subjected to exogenous
β-adrenergic stimulation.
4. Discussion
Despite extensive electrophysiological characterization of
CFTR in cardiac myocytes, its role in cardiac physiology remains
unclear. We previously showed that CFTR is involved in
maintaining un-stimulated [5] and β-adrenergic stimulated [6]
contraction of neonatal ventricular myocytes, while others have
shown CFTR's involvement in the heart's response to ischemia
[7,9]. These, coupled with reports of ventricular arrhythmias,
cardiomyopathy, and post-mortem fibrosis and necrosis in CF
patients [19–21], prompt investigation into the cardiac health
of individuals with CF. For the first time, we have examined,
in vivo, the physiological effect of chronic CFTR loss on the heart
in a manner that allows for evaluation of primary cardiovascular
function.ic measurement of heart function in WT andΔF508 mice (n=10). FS: fractional
deceleration time; E′: early diastole; A′: late diastole; S′: peak systolic annular
lues are expressed as means±SEM. *, Pb0.05; **, Pb0.01 vs.WT by Student's
A′
(cm/s)
E′/A′ E/E′ IVCT
(ms)
IVRT
(ms)
Tei index
.4 20.2±1.4 1.31±0.09 31.2±2.0 11.6±1.1 11.5±0.7 0.52±0.03
.7 29.3±1.7** 0.95±0.11* 29.2±2.3 7.4±0.4** 11.0±0.6 0.42±0.02*
Fig. 1. ΔF508 CFTR mice show increased baseline cardiac activity. LV hemodynamic measurements were performed in WT (n=9) and ΔF508 (n=12) mice via
catheterization. Each circle represents a single mouse, while the line represents the mean.
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Fig. 2. CFTR mutation causes increase in the aortic stiffness. In vivo, aortic compliance was measured using echocardiography in WT and ΔF508 mice (n=10).
A. Representative images of WT and ΔF508 aortic arches using M-mode images presented with values for mean internal diameters (ID) of aorta (Ao) during diastole
(d) and systole (s). B. Distensibility was calculated as the relative change in diameter between systole and diastole. C. Pulse wave velocity-measured aortic stiffness.
D. Representative Doppler flow images during 2 cycles of systole and diastole through the aortic arches of WT and ΔF508 mice. The straight line represents zero
blood velocity with below the line showing velocity of forward flow as blood moves away from probe and above the line showing velocity of retrograde flow as blood
moves towards probe. Values for the mean forward and retrograde velocities are presented. All values are presented as means±SEM. *, Pb0.05; **, Pb0.01;
***, Pb0.001 vs. WT by Student's t-test.
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Fig. 3. Decreased cardiac reserve in ΔF508 mice during β-adrenergic stimulation. LV catheterization-measured hemodynamic changes following stimulation with
serial concentrations of the β1-adrenergic agonist dobutamine in WT (n=9) and ΔF508 (n=12) mice. Data are shown as percent change from the respective baseline
(Fig. 1) for each concentration. Values are expressed as means±SEM. *, Pb0.05; **, Pb0.01; ***, Pb0.001 vs. WT by Student's t-test.
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the left ventricle. Prior histological studies comparing ventricular
areas in ΔF508 and FV/B mice showed specific enlargement of
the left ventricle in ΔF508 mice, with no change in right
ventricular size [22]. These findings are consistent with the fact
thatΔF508mice, unlike CF patients, do not develop lung disease.Thus, for our purpose of examining the primary left ventricular
function, ΔF508 mice proved to be a useful model. The left
ventricular hypertrophy can occur secondary to pressure or
volume overload. Duan et al. found that aortic banding resulted
in faster progression of LV hypertrophy in CFTR null mice,
indicating greater susceptibility to heart failure [23]. On a cellular
523Z.M. Sellers et al. / Journal of Cystic Fibrosis 12 (2013) 517–524level, calcineurin [24] and CaMKII [25] have been heavily
implicated in mediating cardiac myocyte hypertophic response,
with the latter being important for transition to dilated cardiomy-
opathy [26]. The potential role of CaMKII in ΔF508 hearts is
intriguing, as we have previously shown that ΔF508 neonatal
cardiomyocytes have an increased reliance on CaMKII to
maintain normal contraction [5]. It remains to be seen if Ca2+
transients and/or sarcoplasmic reticulum (SERCA) Ca2+ regula-
tion are altered; however, this would support our observed
increases in inotropy and lusitropy [27].
Concentric hypertrophy can lead to diastolic dysfunction due to
abnormal relaxation or restrictive filling. The E, A, and E/A ratios
are indicators of diastolic function and used to indicate normal
function (ENA), abnormal relaxation (EbA), pseudonormal
filling (ENA), or restrictive filling (E≫A) [28]. In our study
the E/A ratio was decreased with ENA, which could represent
psuedonormal filling, however, the E/E′ ratio, which is used
clinically to diagnose diastolic dysfunction was not changed in
ΔF508 mice. Abnormal relaxation, associated with hypertension,
ischemic cardiomyopathy, and left ventricular hypertrophy, is
usually indicated by EbA, prolonged IVRT, and prolonged DT;
none of which we observed in our studies. However, as indicated
above, ENA values can represent normal cardiac function or
pseudonormal function, which is the transition between abnormal
relaxation and restrictive filling, and is characterized by normal
diastolic filling values. With pseudonormal function, active
myocardial relaxation, as occurs during early diastole (E′), can
be mildly decreased, while late diastolic passive myocardial
distention caused by atrial contraction (A′) can increase. Using
these measurements, normal function is represented by E′/A′N1.
In our tissue Doppler studies, ΔF508 hearts displayed no change
in early diastole, but had significantly increased atrial contraction
velocities, resulting in a E′/A′ ratiob1, which was significantly
less than WT mice. Thus, it is possible that ΔF508 mouse hearts
display signs of pseudonormal or early mild diastolic dysfunction
with alterations in the passive left ventricular relaxation, however,
targeted investigation of this in future studies is necessary.
Responsiveness to exercise is an important prognostic indicator
for cardiovascular disease [29]. In lieu of exercise, we exposed
ΔF508 mice to increasing concentrations of the β-adrenergic
agonist, dobutamine. While ΔF508 mice retained the ability to
respond to stimulation, they had a significantly reduced cardiac
reserve, with attenuated changes in +dP/dt, −dP/dt, and LV
pressure. A previous study found that 51% of CF patients had
decreased ejection fraction in response to exercise [30]. While this
study contained patients with severe lung dysfunction, the effect
of which cannot be discounted, we propose that limitations of
myocardial recruitment, in part due to increased basal demands,
may play a role in this attenuated response.
In addition to imaging the heart, we examined, for the first
time, the aortic structure and function of CF mice in vivo.
In vitro, CFTR null mice display increased vascular tone and
attenuated vasoactive peptide-induced relaxation [31]. Our
findings that ΔF508 aortas have decreased internal diameters,
are less distensible, and are stiffer, agree with in vitro data.
These, coupled with our observations of altered aortic flow, are
congruent with altered large vessel hemodynamics in CFpatients at rest [12,14] and during exercise [13]. Despite normal
blood pressures, Hull et al. observed large vessel abnormalities
in CF patients that indicated enhanced vascular aging [14].
Recently, Hull et al. have shown that decreasing systemic
inflammation through short-course IV antibiotics can improve
central hemodynamics [15]. It is unclear if systemic inflamma-
tion contributes to any of our results, but it is clear that in
addition to cardiac function, it is important to elucidate the role
of large vessel reactivity and hemodynamics in CF to determine
the cardiovascular risk for these patients.
While once a childhood disease, advances in research and
clinical care have resulted in a CF population where at least
50% of patients are now adults (www.cff.org). Our studies were
done in adult mice 16–20 weeks old, which would correspond
to a young adult in humans given an average life expectancy of
2 years for C57/BL6 mice. With aortic stiffness identified in
CF children [12], it is possible that the left ventricular changes
may be seen in CF at a young age. Additionally, since age is a
known risk factor for cardiovascular disease, we postulate that
as individuals with CF age they may be at increased risk for
cardiovascular disease compared to their non-CF counterparts.
While it is clear that decreased pulmonary function in CF
affects right ventricular function, we have shown that the left
ventricular and aortic functions are also affected by CFTR loss.
These findings provide compelling reasons to examine the
cardiovascular function of CF patients in more detail.
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